ILLUMINA, INC. is 24.0x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($24.84 B vs $1.03 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EYPT | ILMN |
|---|---|---|
| Market cap | $1.03 B | $24.84 B |
| US-listed rank | #2607 | #539 |
| Revenue (latest FY) | $31.37M | $4.34B |
| Net income (latest FY) | -$231.96M | $850.00M |
| Net margin | -739.4% | 19.6% |
| P/E (trailing FY) | - | 29.2 |
| SEC filings | 1,308 | 3,713 |
ILLUMINA, INC. is 24.0x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($24.84 B vs $1.03 B).
In their latest fiscal years, EyePoint Pharmaceuticals, Inc. reported $31.37M in revenue while ILLUMINA, INC. reported $4.34B.
Full pages: EyePoint Pharmaceuticals, Inc. and ILLUMINA, INC., or browse the full rankings.